Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBT: 2014-2024

Historic EBT for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$567.6 million.

  • Ultragenyx Pharmaceutical's EBT fell 34.78% to -$179.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$576.7 million, marking a year-over-year decrease of 2.79%. This contributed to the annual value of -$567.6 million for FY2024, which is 6.72% up from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's EBT stood at -$567.6 million, which was up 6.72% from -$608.5 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's EBT's 5-year high stood at -$189.4 million during FY2020, with a 5-year trough of -$703.4 million in FY2022.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median EBT value was -$608.5 million (recorded in 2023), while the average stood at -$626.5 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's EBT surged by 52.60% in 2020 and then crashed by 140.34% in 2021.
  • Ultragenyx Pharmaceutical's EBT (Yearly) stood at -$189.4 million in 2020, then slumped by 140.34% to -$455.3 million in 2021, then crashed by 54.49% to -$703.4 million in 2022, then increased by 13.50% to -$608.5 million in 2023, then rose by 6.72% to -$567.6 million in 2024.